Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 71 | 2023 | 5369 | 3.850 |
Why?
|
Rectal Neoplasms | 27 | 2021 | 1156 | 2.920 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 88 | 2023 | 11735 | 2.880 |
Why?
|
Adenocarcinoma | 53 | 2023 | 6345 | 2.510 |
Why?
|
Deoxycytidine | 34 | 2020 | 878 | 2.340 |
Why?
|
Carcinoma, Pancreatic Ductal | 25 | 2023 | 1727 | 2.220 |
Why?
|
Neoadjuvant Therapy | 37 | 2023 | 2827 | 2.040 |
Why?
|
Fluorouracil | 54 | 2023 | 1642 | 1.910 |
Why?
|
Colorectal Neoplasms | 36 | 2023 | 6927 | 1.860 |
Why?
|
Peritoneal Neoplasms | 7 | 2022 | 710 | 1.780 |
Why?
|
Anus Neoplasms | 13 | 2020 | 329 | 1.660 |
Why?
|
Camptothecin | 20 | 2017 | 591 | 1.520 |
Why?
|
Gastrointestinal Neoplasms | 14 | 2023 | 955 | 1.410 |
Why?
|
Leucovorin | 27 | 2023 | 643 | 1.320 |
Why?
|
Organoplatinum Compounds | 22 | 2017 | 407 | 1.120 |
Why?
|
Antineoplastic Agents | 46 | 2023 | 13635 | 1.100 |
Why?
|
Liver Neoplasms | 25 | 2019 | 4309 | 0.990 |
Why?
|
Hyperthermia, Induced | 3 | 2021 | 417 | 0.960 |
Why?
|
Colonic Neoplasms | 13 | 2018 | 2533 | 0.960 |
Why?
|
Combined Modality Therapy | 31 | 2022 | 8516 | 0.920 |
Why?
|
Bile Duct Neoplasms | 10 | 2024 | 606 | 0.920 |
Why?
|
Carcinoma, Hepatocellular | 15 | 2019 | 2292 | 0.910 |
Why?
|
Neoplasm Staging | 46 | 2021 | 11118 | 0.850 |
Why?
|
Cholangiocarcinoma | 9 | 2024 | 553 | 0.800 |
Why?
|
Infusion Pumps | 1 | 2022 | 163 | 0.760 |
Why?
|
Hepatic Artery | 1 | 2022 | 232 | 0.740 |
Why?
|
Maximum Tolerated Dose | 23 | 2023 | 883 | 0.720 |
Why?
|
Paclitaxel | 7 | 2020 | 1730 | 0.680 |
Why?
|
Neoplasms | 38 | 2022 | 22131 | 0.660 |
Why?
|
Albumins | 3 | 2020 | 575 | 0.660 |
Why?
|
Stomach Neoplasms | 8 | 2021 | 1459 | 0.640 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2021 | 9277 | 0.640 |
Why?
|
ras Proteins | 9 | 2014 | 1054 | 0.620 |
Why?
|
Chemotherapy, Adjuvant | 17 | 2020 | 3514 | 0.600 |
Why?
|
Medical Oncology | 4 | 2020 | 2317 | 0.590 |
Why?
|
Mitomycin | 5 | 2019 | 263 | 0.590 |
Why?
|
Antimetabolites, Antineoplastic | 12 | 2015 | 645 | 0.570 |
Why?
|
Middle Aged | 177 | 2024 | 220603 | 0.560 |
Why?
|
Humans | 268 | 2024 | 760740 | 0.560 |
Why?
|
Aged | 156 | 2024 | 169092 | 0.550 |
Why?
|
Dioxoles | 5 | 2005 | 95 | 0.540 |
Why?
|
Pseudomyxoma Peritonei | 2 | 2013 | 21 | 0.540 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2019 | 278 | 0.520 |
Why?
|
Proto-Oncogene Proteins B-raf | 11 | 2023 | 2057 | 0.520 |
Why?
|
Disease-Free Survival | 27 | 2019 | 6807 | 0.510 |
Why?
|
Neoplasm Metastasis | 21 | 2020 | 4910 | 0.510 |
Why?
|
Carboxylesterase | 1 | 2015 | 31 | 0.500 |
Why?
|
Male | 191 | 2024 | 360402 | 0.500 |
Why?
|
Survival Rate | 31 | 2024 | 12719 | 0.490 |
Why?
|
Isoquinolines | 5 | 2005 | 352 | 0.490 |
Why?
|
Burnout, Professional | 1 | 2023 | 703 | 0.480 |
Why?
|
Carcinoma | 4 | 2016 | 2328 | 0.480 |
Why?
|
Aged, 80 and over | 78 | 2024 | 58919 | 0.470 |
Why?
|
Standard of Care | 3 | 2022 | 551 | 0.460 |
Why?
|
Esophageal Neoplasms | 8 | 2021 | 1657 | 0.460 |
Why?
|
Female | 185 | 2024 | 392203 | 0.450 |
Why?
|
Antibodies, Monoclonal | 13 | 2020 | 9171 | 0.440 |
Why?
|
Treatment Outcome | 65 | 2023 | 64572 | 0.420 |
Why?
|
Proto-Oncogene Proteins | 10 | 2014 | 4512 | 0.410 |
Why?
|
Antineoplastic Agents, Alkylating | 6 | 2009 | 617 | 0.410 |
Why?
|
Taxoids | 4 | 2006 | 667 | 0.380 |
Why?
|
Adult | 127 | 2024 | 220995 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2020 | 4021 | 0.380 |
Why?
|
Peritoneum | 1 | 2012 | 225 | 0.370 |
Why?
|
Sirolimus | 5 | 2013 | 1533 | 0.370 |
Why?
|
Palliative Care | 8 | 2022 | 3593 | 0.370 |
Why?
|
Lung Neoplasms | 9 | 2020 | 13383 | 0.360 |
Why?
|
Community-Institutional Relations | 1 | 2012 | 206 | 0.360 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2012 | 678 | 0.360 |
Why?
|
Boronic Acids | 4 | 2008 | 915 | 0.360 |
Why?
|
Cecal Neoplasms | 1 | 2010 | 26 | 0.360 |
Why?
|
Community-Based Participatory Research | 1 | 2012 | 221 | 0.350 |
Why?
|
Pancreatectomy | 7 | 2023 | 811 | 0.350 |
Why?
|
Clinical Trials as Topic | 5 | 2020 | 7995 | 0.350 |
Why?
|
Prognosis | 37 | 2024 | 29601 | 0.350 |
Why?
|
Lymphopenia | 2 | 2024 | 281 | 0.350 |
Why?
|
Heparin | 1 | 2017 | 1632 | 0.350 |
Why?
|
Neoplastic Cells, Circulating | 4 | 2020 | 943 | 0.350 |
Why?
|
Medication Errors | 1 | 2016 | 783 | 0.340 |
Why?
|
Carcinoid Tumor | 5 | 2018 | 224 | 0.330 |
Why?
|
Pyrazines | 4 | 2008 | 1202 | 0.320 |
Why?
|
Mutation | 21 | 2023 | 30015 | 0.310 |
Why?
|
Infusions, Intravenous | 18 | 2014 | 2214 | 0.300 |
Why?
|
Angiogenesis Inhibitors | 10 | 2014 | 2048 | 0.300 |
Why?
|
Drug Administration Schedule | 21 | 2015 | 4845 | 0.290 |
Why?
|
Pyrroles | 5 | 2014 | 1125 | 0.270 |
Why?
|
Positron-Emission Tomography | 11 | 2022 | 6483 | 0.270 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 9 | 2015 | 1745 | 0.270 |
Why?
|
Neuroendocrine Tumors | 7 | 2013 | 641 | 0.260 |
Why?
|
Academic Medical Centers | 2 | 2016 | 2756 | 0.260 |
Why?
|
Survival Analysis | 25 | 2019 | 10072 | 0.260 |
Why?
|
Quinazolines | 9 | 2013 | 1371 | 0.250 |
Why?
|
Gene Amplification | 3 | 2020 | 1087 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 12 | 2020 | 6473 | 0.250 |
Why?
|
Pancreas | 2 | 2017 | 1691 | 0.240 |
Why?
|
Massachusetts | 12 | 2020 | 8835 | 0.240 |
Why?
|
Radiotherapy Dosage | 13 | 2019 | 2897 | 0.240 |
Why?
|
Radiotherapy | 6 | 2021 | 1497 | 0.240 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2018 | 801 | 0.240 |
Why?
|
Hospitalization | 9 | 2022 | 10708 | 0.230 |
Why?
|
Retrospective Studies | 45 | 2024 | 80583 | 0.230 |
Why?
|
Biliary Tract Neoplasms | 2 | 2020 | 185 | 0.230 |
Why?
|
Indoles | 5 | 2011 | 1830 | 0.220 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 86 | 0.220 |
Why?
|
Intraoperative Care | 2 | 2018 | 767 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 17 | 2023 | 10754 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2020 | 8542 | 0.220 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2015 | 937 | 0.220 |
Why?
|
Disease Progression | 18 | 2022 | 13495 | 0.210 |
Why?
|
Quality of Life | 10 | 2020 | 13359 | 0.210 |
Why?
|
Follow-Up Studies | 22 | 2024 | 39062 | 0.210 |
Why?
|
Imidazoles | 3 | 2015 | 1175 | 0.210 |
Why?
|
Photons | 2 | 2019 | 589 | 0.210 |
Why?
|
Bile Ducts, Intrahepatic | 4 | 2014 | 296 | 0.200 |
Why?
|
Drug Resistance, Neoplasm | 12 | 2020 | 5304 | 0.200 |
Why?
|
Immunoconjugates | 2 | 2023 | 951 | 0.200 |
Why?
|
Infusions, Intra-Arterial | 1 | 2022 | 221 | 0.200 |
Why?
|
Anal Canal | 4 | 2020 | 374 | 0.200 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 225 | 0.190 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2006 | 487 | 0.190 |
Why?
|
Losartan | 2 | 2023 | 263 | 0.190 |
Why?
|
Cisplatin | 6 | 2013 | 1650 | 0.190 |
Why?
|
Benzodiazepines | 2 | 2005 | 1133 | 0.190 |
Why?
|
Radiodermatitis | 2 | 2019 | 60 | 0.180 |
Why?
|
Rectum | 2 | 2018 | 891 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 571 | 0.180 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2000 | 326 | 0.180 |
Why?
|
Feasibility Studies | 7 | 2023 | 5239 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2022 | 10203 | 0.180 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2016 | 1784 | 0.180 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.180 |
Why?
|
Phosphatidylinositol 3-Kinases | 6 | 2014 | 2863 | 0.170 |
Why?
|
HMGA2 Protein | 1 | 2020 | 102 | 0.170 |
Why?
|
Neoplasm, Residual | 3 | 2021 | 1008 | 0.170 |
Why?
|
Colectomy | 3 | 2011 | 686 | 0.170 |
Why?
|
Patient Care Team | 2 | 2020 | 2515 | 0.160 |
Why?
|
Radiation Injuries | 5 | 2020 | 1189 | 0.160 |
Why?
|
Heparitin Sulfate | 1 | 2020 | 223 | 0.160 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2222 | 0.160 |
Why?
|
Neutropenia | 5 | 2017 | 885 | 0.160 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7390 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 116 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 350 | 0.150 |
Why?
|
Gallbladder Neoplasms | 2 | 2011 | 189 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2000 | 420 | 0.150 |
Why?
|
Organoids | 2 | 2022 | 744 | 0.150 |
Why?
|
Administration, Oral | 11 | 2014 | 4010 | 0.150 |
Why?
|
Chromogranins | 1 | 2018 | 160 | 0.150 |
Why?
|
Physician's Role | 2 | 2020 | 917 | 0.140 |
Why?
|
Personal Satisfaction | 1 | 2022 | 645 | 0.140 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2020 | 424 | 0.140 |
Why?
|
Chemokine CCL2 | 1 | 2019 | 602 | 0.140 |
Why?
|
Angiotensins | 1 | 2017 | 142 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 250 | 0.140 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2018 | 195 | 0.130 |
Why?
|
Tetrahydroisoquinolines | 5 | 2005 | 81 | 0.130 |
Why?
|
Patient-Centered Care | 2 | 2019 | 1419 | 0.130 |
Why?
|
Appendiceal Neoplasms | 1 | 2018 | 155 | 0.130 |
Why?
|
Sarcoma | 5 | 2005 | 1800 | 0.130 |
Why?
|
Models, Chemical | 5 | 2007 | 611 | 0.130 |
Why?
|
Carcinoembryonic Antigen | 3 | 2014 | 335 | 0.130 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 733 | 0.130 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2018 | 485 | 0.130 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 3196 | 0.130 |
Why?
|
Hospitals, General | 1 | 2020 | 798 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 456 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2022 | 2008 | 0.130 |
Why?
|
Cellulitis | 1 | 2017 | 209 | 0.130 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 3868 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 9 | 2023 | 5672 | 0.130 |
Why?
|
Propensity Score | 2 | 2023 | 1912 | 0.130 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2016 | 214 | 0.130 |
Why?
|
Prospective Studies | 20 | 2021 | 54364 | 0.120 |
Why?
|
Guanylate Cyclase | 1 | 2016 | 205 | 0.120 |
Why?
|
Area Under Curve | 7 | 2005 | 1635 | 0.120 |
Why?
|
Resuscitation Orders | 1 | 2017 | 270 | 0.120 |
Why?
|
RNA, Neoplasm | 2 | 2017 | 749 | 0.120 |
Why?
|
Time Factors | 13 | 2019 | 39908 | 0.120 |
Why?
|
Pyrimidines | 4 | 2016 | 3027 | 0.120 |
Why?
|
Phosphoramide Mustards | 1 | 2014 | 18 | 0.120 |
Why?
|
Farnesyltranstransferase | 2 | 2005 | 71 | 0.120 |
Why?
|
Early Detection of Cancer | 3 | 2019 | 3196 | 0.120 |
Why?
|
Goblet Cells | 1 | 2018 | 298 | 0.120 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 529 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 233 | 0.120 |
Why?
|
Patient Selection | 3 | 2012 | 4237 | 0.120 |
Why?
|
Affect | 2 | 2020 | 1486 | 0.120 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1626 | 0.120 |
Why?
|
Collagen | 2 | 2002 | 2634 | 0.120 |
Why?
|
Endostatins | 3 | 2006 | 168 | 0.120 |
Why?
|
Triazoles | 1 | 2020 | 903 | 0.120 |
Why?
|
Esophagogastric Junction | 3 | 2020 | 347 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 36401 | 0.110 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1743 | 0.110 |
Why?
|
Spermine | 1 | 2013 | 70 | 0.110 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2015 | 332 | 0.110 |
Why?
|
Nitroimidazoles | 1 | 2014 | 117 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 733 | 0.110 |
Why?
|
Lymphatic Metastasis | 4 | 2017 | 2913 | 0.110 |
Why?
|
Precancerous Conditions | 2 | 2017 | 982 | 0.110 |
Why?
|
Ethics, Medical | 1 | 1999 | 783 | 0.110 |
Why?
|
Treatment Failure | 5 | 2019 | 2635 | 0.110 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2017 | 517 | 0.110 |
Why?
|
Sexual Behavior | 2 | 2020 | 2187 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 9 | 2021 | 20556 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1112 | 0.100 |
Why?
|
Risk Management | 1 | 2016 | 557 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15829 | 0.100 |
Why?
|
Glutarates | 1 | 2014 | 243 | 0.100 |
Why?
|
Pyridines | 3 | 2021 | 2875 | 0.100 |
Why?
|
Dacarbazine | 3 | 2013 | 559 | 0.100 |
Why?
|
Carcinoma, Papillary | 1 | 2017 | 785 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2011 | 2057 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1422 | 0.100 |
Why?
|
Epirubicin | 2 | 2016 | 81 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.100 |
Why?
|
DNA Mutational Analysis | 4 | 2014 | 4110 | 0.090 |
Why?
|
Vena Cava Filters | 1 | 2014 | 261 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2020 | 1890 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 1655 | 0.090 |
Why?
|
Cell Separation | 1 | 2017 | 1718 | 0.090 |
Why?
|
Length of Stay | 4 | 2018 | 6418 | 0.090 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 933 | 0.090 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1096 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2018 | 1528 | 0.090 |
Why?
|
Protein Kinases | 2 | 2008 | 1606 | 0.090 |
Why?
|
Mental Disorders | 2 | 2022 | 6826 | 0.090 |
Why?
|
Appointments and Schedules | 1 | 2015 | 442 | 0.090 |
Why?
|
Hospice Care | 1 | 2017 | 677 | 0.090 |
Why?
|
Salvage Therapy | 3 | 2007 | 1263 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2013 | 12966 | 0.090 |
Why?
|
Doxorubicin | 4 | 2006 | 2224 | 0.090 |
Why?
|
Colon, Sigmoid | 1 | 2011 | 124 | 0.090 |
Why?
|
Sensory Receptor Cells | 1 | 2015 | 508 | 0.090 |
Why?
|
Enzyme Inhibitors | 3 | 2005 | 3705 | 0.090 |
Why?
|
Peptide Fragments | 2 | 2002 | 5109 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12448 | 0.090 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2005 | 620 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3634 | 0.090 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 768 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2018 | 2821 | 0.090 |
Why?
|
Signal Transduction | 7 | 2018 | 23415 | 0.090 |
Why?
|
Lipid Metabolism | 1 | 2018 | 1896 | 0.080 |
Why?
|
Depression | 3 | 2018 | 8132 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2942 | 0.080 |
Why?
|
Device Removal | 1 | 2014 | 629 | 0.080 |
Why?
|
Piperazines | 3 | 2021 | 2521 | 0.080 |
Why?
|
Vulnerable Populations | 1 | 2015 | 705 | 0.080 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2015 | 709 | 0.080 |
Why?
|
DNA Damage | 1 | 2019 | 2445 | 0.080 |
Why?
|
Vagina | 1 | 2014 | 841 | 0.080 |
Why?
|
Polymorphism, Genetic | 3 | 2008 | 4242 | 0.080 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 83 | 0.080 |
Why?
|
Microsatellite Instability | 2 | 2015 | 716 | 0.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 3 | 2010 | 664 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1999 | 0.080 |
Why?
|
CA-19-9 Antigen | 2 | 2022 | 106 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2021 | 9026 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2022 | 2916 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2014 | 899 | 0.080 |
Why?
|
Wnt Proteins | 1 | 2012 | 718 | 0.080 |
Why?
|
Europe | 1 | 2015 | 3415 | 0.080 |
Why?
|
Patient Discharge | 2 | 2020 | 3442 | 0.080 |
Why?
|
Intestine, Small | 2 | 2012 | 1207 | 0.080 |
Why?
|
Whole Body Imaging | 1 | 2010 | 283 | 0.080 |
Why?
|
Radiopharmaceuticals | 3 | 2022 | 2650 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2553 | 0.070 |
Why?
|
Radiosurgery | 1 | 2017 | 1339 | 0.070 |
Why?
|
Surgical Wound Dehiscence | 1 | 2009 | 212 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Disease Management | 2 | 2016 | 2506 | 0.070 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 328 | 0.070 |
Why?
|
RNA, Messenger | 4 | 2017 | 12759 | 0.070 |
Why?
|
Floxuridine | 1 | 2006 | 44 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1656 | 0.070 |
Why?
|
Pyrimidinones | 2 | 2023 | 385 | 0.070 |
Why?
|
Cohort Studies | 11 | 2020 | 41464 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2924 | 0.070 |
Why?
|
Oxonic Acid | 1 | 2006 | 31 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2010 | 3492 | 0.070 |
Why?
|
Tegafur | 1 | 2006 | 39 | 0.070 |
Why?
|
GTP Phosphohydrolases | 3 | 2014 | 517 | 0.070 |
Why?
|
Adaptation, Psychological | 1 | 2017 | 2632 | 0.070 |
Why?
|
Tumor Burden | 4 | 2017 | 1892 | 0.070 |
Why?
|
Receptors, Growth Factor | 1 | 2007 | 326 | 0.070 |
Why?
|
Antidepressive Agents | 1 | 2018 | 2896 | 0.070 |
Why?
|
Oligopeptides | 2 | 2016 | 1185 | 0.070 |
Why?
|
Expert Testimony | 1 | 2008 | 364 | 0.060 |
Why?
|
Digestive System Neoplasms | 1 | 2006 | 83 | 0.060 |
Why?
|
Double-Blind Method | 1 | 2020 | 12333 | 0.060 |
Why?
|
Thalidomide | 3 | 2006 | 885 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 367 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 2 | 2005 | 1158 | 0.060 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2006 | 128 | 0.060 |
Why?
|
Ifosfamide | 1 | 2006 | 232 | 0.060 |
Why?
|
Streptozocin | 2 | 2004 | 193 | 0.060 |
Why?
|
Self Care | 2 | 2022 | 796 | 0.060 |
Why?
|
Pancreaticoduodenectomy | 3 | 2015 | 509 | 0.060 |
Why?
|
Epithelial Cells | 1 | 2017 | 3672 | 0.060 |
Why?
|
Superoxide Dismutase | 1 | 2008 | 593 | 0.060 |
Why?
|
Gastrointestinal Diseases | 2 | 2012 | 1202 | 0.060 |
Why?
|
alpha-Fetoproteins | 1 | 2006 | 222 | 0.060 |
Why?
|
Hydrazines | 1 | 2007 | 223 | 0.060 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 3593 | 0.060 |
Why?
|
Haemophilus Vaccines | 1 | 2005 | 71 | 0.060 |
Why?
|
raf Kinases | 1 | 2005 | 118 | 0.060 |
Why?
|
Mice, Inbred NOD | 2 | 2020 | 1827 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5838 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2011 | 2456 | 0.060 |
Why?
|
Benzenesulfonates | 1 | 2005 | 166 | 0.060 |
Why?
|
Peroxidase | 1 | 2008 | 610 | 0.060 |
Why?
|
Tetanus Toxoid | 1 | 2005 | 188 | 0.060 |
Why?
|
src-Family Kinases | 1 | 2007 | 535 | 0.060 |
Why?
|
Risk Factors | 8 | 2016 | 74128 | 0.060 |
Why?
|
Perioperative Care | 1 | 2012 | 1037 | 0.060 |
Why?
|
Patient Compliance | 1 | 2015 | 2688 | 0.060 |
Why?
|
Vinblastine | 1 | 2006 | 488 | 0.060 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 1 | 2004 | 17 | 0.060 |
Why?
|
MicroRNAs | 1 | 2020 | 3802 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5696 | 0.060 |
Why?
|
Pyridones | 2 | 2023 | 808 | 0.060 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 244 | 0.060 |
Why?
|
Thymidylate Synthase | 1 | 2004 | 74 | 0.060 |
Why?
|
Purine Nucleosides | 1 | 2003 | 30 | 0.060 |
Why?
|
Catheterization, Central Venous | 1 | 2009 | 526 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2004 | 727 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 4010 | 0.060 |
Why?
|
Pain | 3 | 2014 | 5062 | 0.060 |
Why?
|
Genes, ras | 2 | 2018 | 654 | 0.060 |
Why?
|
Pheochromocytoma | 1 | 2006 | 328 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8652 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2017 | 5292 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 3680 | 0.050 |
Why?
|
Adenomatous Polyposis Coli Protein | 2 | 2014 | 180 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 86 | 0.050 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2006 | 1320 | 0.050 |
Why?
|
Staurosporine | 1 | 2004 | 242 | 0.050 |
Why?
|
Morpholines | 1 | 2006 | 581 | 0.050 |
Why?
|
Drug Synergism | 1 | 2007 | 1756 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2019 | 12043 | 0.050 |
Why?
|
Radioisotope Teletherapy | 1 | 2002 | 15 | 0.050 |
Why?
|
Chromans | 1 | 2002 | 117 | 0.050 |
Why?
|
Mitomycins | 1 | 2002 | 46 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
Lymph Node Excision | 1 | 2008 | 1269 | 0.050 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2006 | 339 | 0.050 |
Why?
|
CpG Islands | 1 | 2007 | 1192 | 0.050 |
Why?
|
Risk Assessment | 6 | 2017 | 23974 | 0.050 |
Why?
|
Pilot Projects | 3 | 2021 | 8619 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 2509 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5319 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6126 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 160 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2010 | 11069 | 0.050 |
Why?
|
Genotype | 5 | 2017 | 12977 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 397 | 0.050 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2004 | 333 | 0.050 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1866 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 127 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2017 | 2010 | 0.050 |
Why?
|
Age Factors | 5 | 2023 | 18381 | 0.050 |
Why?
|
Anxiety | 3 | 2022 | 4573 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 366 | 0.050 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3239 | 0.040 |
Why?
|
Portal Vein | 1 | 2023 | 431 | 0.040 |
Why?
|
Toxicity Tests | 1 | 2001 | 115 | 0.040 |
Why?
|
United States | 4 | 2019 | 72292 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2003 | 1376 | 0.040 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2006 | 732 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 235 | 0.040 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2018 | 4575 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 638 | 0.040 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 15250 | 0.040 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2002 | 349 | 0.040 |
Why?
|
Anemia, Hemolytic | 1 | 2001 | 162 | 0.040 |
Why?
|
Preoperative Period | 1 | 2022 | 550 | 0.040 |
Why?
|
Thiazolidinediones | 1 | 2002 | 460 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 783 | 0.040 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 16968 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 636 | 0.040 |
Why?
|
Inpatients | 2 | 2021 | 2545 | 0.040 |
Why?
|
Aspartate Aminotransferases | 1 | 2001 | 414 | 0.040 |
Why?
|
Collagen Type XVIII | 1 | 1999 | 52 | 0.040 |
Why?
|
Pneumonectomy | 1 | 2006 | 1119 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 105 | 0.040 |
Why?
|
Enzyme Repression | 1 | 2018 | 30 | 0.040 |
Why?
|
Intraoperative Period | 2 | 2013 | 510 | 0.040 |
Why?
|
Young Adult | 8 | 2020 | 59191 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 702 | 0.040 |
Why?
|
Education, Medical, Continuing | 1 | 2004 | 825 | 0.040 |
Why?
|
Schizophrenia | 1 | 2017 | 6929 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2373 | 0.040 |
Why?
|
Preoperative Care | 2 | 2013 | 2242 | 0.040 |
Why?
|
Safety | 3 | 2012 | 1149 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2001 | 601 | 0.040 |
Why?
|
Videoconferencing | 1 | 2020 | 203 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2000 | 629 | 0.040 |
Why?
|
Biopsy | 3 | 2018 | 6763 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 858 | 0.040 |
Why?
|
Wound Healing | 1 | 2009 | 2802 | 0.040 |
Why?
|
Interprofessional Relations | 1 | 2004 | 991 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2005 | 1037 | 0.040 |
Why?
|
Liver Function Tests | 2 | 2013 | 524 | 0.040 |
Why?
|
Cause of Death | 2 | 2019 | 3683 | 0.040 |
Why?
|
Mice, 129 Strain | 1 | 2018 | 370 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 338 | 0.040 |
Why?
|
Transcription Factor TFIIIA | 1 | 2016 | 24 | 0.040 |
Why?
|
Animals | 9 | 2022 | 168202 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 561 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2000 | 435 | 0.040 |
Why?
|
Radiography | 4 | 2010 | 6961 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 4 | 2018 | 17878 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5780 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2425 | 0.030 |
Why?
|
Sequence Analysis, RNA | 2 | 2017 | 2013 | 0.030 |
Why?
|
Education, Medical | 1 | 2008 | 1725 | 0.030 |
Why?
|
Caregivers | 2 | 2022 | 2241 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2000 | 857 | 0.030 |
Why?
|
Thrombocytopenia | 2 | 2006 | 1182 | 0.030 |
Why?
|
Transplantation, Heterologous | 2 | 2017 | 2382 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 361 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 106 | 0.030 |
Why?
|
Pelvis | 1 | 2020 | 732 | 0.030 |
Why?
|
Psychological Tests | 1 | 2018 | 639 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 371 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2017 | 378 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1614 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1008 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 778 | 0.030 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2005 | 1228 | 0.030 |
Why?
|
Ontario | 2 | 2008 | 397 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 2644 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2018 | 1748 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2625 | 0.030 |
Why?
|
Thiazoles | 1 | 2002 | 1517 | 0.030 |
Why?
|
Oxaloacetates | 1 | 2014 | 5 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 994 | 0.030 |
Why?
|
Pelvic Bones | 1 | 2017 | 270 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2327 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2413 | 0.030 |
Why?
|
Incidence | 3 | 2021 | 21339 | 0.030 |
Why?
|
Base Sequence | 3 | 2012 | 12420 | 0.030 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2015 | 34 | 0.030 |
Why?
|
Hospices | 1 | 2017 | 245 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2020 | 1436 | 0.030 |
Why?
|
Leadership | 1 | 2004 | 1385 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
Oximes | 1 | 2015 | 303 | 0.030 |
Why?
|
Exercise | 1 | 2011 | 5886 | 0.030 |
Why?
|
Hepatectomy | 1 | 2017 | 557 | 0.030 |
Why?
|
Gene Fusion | 1 | 2016 | 356 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2000 | 1117 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 166 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2015 | 2812 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2017 | 963 | 0.030 |
Why?
|
Cytarabine | 2 | 2010 | 697 | 0.030 |
Why?
|
Triage | 1 | 2020 | 984 | 0.030 |
Why?
|
DNA Primers | 2 | 2011 | 2817 | 0.030 |
Why?
|
Retreatment | 1 | 2014 | 596 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3607 | 0.030 |
Why?
|
Membrane Proteins | 3 | 2014 | 7847 | 0.030 |
Why?
|
Liver | 3 | 2007 | 7512 | 0.030 |
Why?
|
Wnt2 Protein | 1 | 2012 | 28 | 0.030 |
Why?
|
Contact Inhibition | 1 | 2012 | 46 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1550 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2022 | 9417 | 0.030 |
Why?
|
DNA Methylation | 1 | 2007 | 4392 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 271 | 0.030 |
Why?
|
Diarrhea | 2 | 2012 | 1317 | 0.030 |
Why?
|
Leukemia | 1 | 2000 | 1520 | 0.030 |
Why?
|
Hepatitis B, Chronic | 1 | 2017 | 410 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1589 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1348 | 0.030 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2017 | 432 | 0.030 |
Why?
|
Intestine, Large | 1 | 2012 | 69 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1723 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2012 | 5811 | 0.030 |
Why?
|
Biopsy, Needle | 2 | 2010 | 1624 | 0.030 |
Why?
|
Models, Statistical | 2 | 2018 | 5074 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2713 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2017 | 1226 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2018 | 2231 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2013 | 880 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 422 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2017 | 905 | 0.020 |
Why?
|
Reminder Systems | 1 | 2015 | 386 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2019 | 1505 | 0.020 |
Why?
|
Sample Size | 1 | 2015 | 838 | 0.020 |
Why?
|
Needs Assessment | 1 | 2017 | 1139 | 0.020 |
Why?
|
Telephone | 1 | 2015 | 626 | 0.020 |
Why?
|
Gastrectomy | 1 | 2016 | 671 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2017 | 22153 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1034 | 0.020 |
Why?
|
Logistic Models | 2 | 2017 | 13248 | 0.020 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2012 | 254 | 0.020 |
Why?
|
SEER Program | 1 | 2016 | 1450 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 2010 | 372 | 0.020 |
Why?
|
Urogenital System | 1 | 2010 | 88 | 0.020 |
Why?
|
Cell Cycle Proteins | 2 | 2016 | 3447 | 0.020 |
Why?
|
Defecation | 1 | 2012 | 190 | 0.020 |
Why?
|
Adolescent | 4 | 2020 | 88247 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2022 | 14649 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2012 | 370 | 0.020 |
Why?
|
Somatostatin | 1 | 2012 | 447 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3727 | 0.020 |
Why?
|
Lymphatic Irradiation | 1 | 2010 | 115 | 0.020 |
Why?
|
Fatty Acids | 1 | 2018 | 1808 | 0.020 |
Why?
|
Health Status | 2 | 2017 | 4076 | 0.020 |
Why?
|
Immunotherapy | 2 | 2021 | 4642 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 20988 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3037 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1113 | 0.020 |
Why?
|
Benzamides | 2 | 2006 | 1371 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2017 | 992 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.020 |
Why?
|
Transcription Factors | 2 | 2014 | 12116 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2022 | 3451 | 0.020 |
Why?
|
Diphosphonates | 1 | 2014 | 635 | 0.020 |
Why?
|
Recurrence | 2 | 2011 | 8426 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2017 | 1956 | 0.020 |
Why?
|
Failure to Thrive | 1 | 2009 | 140 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
Smoking | 1 | 2005 | 9054 | 0.020 |
Why?
|
Cost of Illness | 1 | 2018 | 1937 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7196 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5201 | 0.020 |
Why?
|
Papillomavirus Infections | 1 | 2000 | 1612 | 0.020 |
Why?
|
Drug Substitution | 1 | 2010 | 290 | 0.020 |
Why?
|
Psychometrics | 1 | 2017 | 3062 | 0.020 |
Why?
|
Cell Lineage | 1 | 2017 | 2553 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 548 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 386 | 0.020 |
Why?
|
Mice | 4 | 2017 | 81368 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 454 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3599 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 6016 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1608 | 0.020 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1161 | 0.020 |
Why?
|
Bone Marrow | 1 | 2017 | 2909 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 496 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 679 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1643 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2017 | 1927 | 0.020 |
Why?
|
Cell Count | 1 | 2010 | 1834 | 0.020 |
Why?
|
Digestive System Surgical Procedures | 1 | 2011 | 571 | 0.020 |
Why?
|
Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7236 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2006 | 46 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1386 | 0.020 |
Why?
|
Vomiting | 1 | 2009 | 651 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 5493 | 0.020 |
Why?
|
Risk | 2 | 2008 | 9603 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2017 | 3461 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 3591 | 0.020 |
Why?
|
Antigens, Neoplasm | 2 | 2005 | 1985 | 0.020 |
Why?
|
Patient Readmission | 1 | 2020 | 3269 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9526 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2017 | 2447 | 0.020 |
Why?
|
Terminal Care | 1 | 2017 | 1755 | 0.020 |
Why?
|
Pyridoxal Phosphate | 1 | 2005 | 121 | 0.020 |
Why?
|
Self Administration | 1 | 2006 | 387 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3606 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4849 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2020 | 14388 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 671 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 1999 | 3882 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2006 | 6520 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6223 | 0.010 |
Why?
|
Edetic Acid | 1 | 2005 | 276 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 319 | 0.010 |
Why?
|
Comorbidity | 2 | 2009 | 10507 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 834 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 360 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2008 | 1575 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2011 | 1483 | 0.010 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1067 | 0.010 |
Why?
|
Peripheral Nervous System | 1 | 2005 | 151 | 0.010 |
Why?
|
Hemoglobins | 1 | 2010 | 1524 | 0.010 |
Why?
|
Nurses | 1 | 2014 | 2477 | 0.010 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 2004 | 93 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2851 | 0.010 |
Why?
|
Antipsychotic Agents | 1 | 2017 | 3067 | 0.010 |
Why?
|
Life Tables | 1 | 2004 | 364 | 0.010 |
Why?
|
Terminally Ill | 1 | 2005 | 240 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14599 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 328 | 0.010 |
Why?
|
Niacinamide | 1 | 2005 | 413 | 0.010 |
Why?
|
Octreotide | 1 | 2004 | 154 | 0.010 |
Why?
|
Stomach | 1 | 2007 | 696 | 0.010 |
Why?
|
Insurance, Health | 1 | 2015 | 2495 | 0.010 |
Why?
|
Leukocytes | 1 | 2010 | 2024 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3419 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5780 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 2004 | 658 | 0.010 |
Why?
|
Drugs, Investigational | 1 | 2004 | 212 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7569 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4810 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9313 | 0.010 |
Why?
|
Topotecan | 1 | 2002 | 131 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20077 | 0.010 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2002 | 106 | 0.010 |
Why?
|
Transaminases | 1 | 2002 | 199 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2008 | 2703 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3351 | 0.010 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2002 | 122 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4058 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2002 | 748 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6774 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2014 | 2568 | 0.010 |
Why?
|
Exons | 1 | 2006 | 2381 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 592 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16572 | 0.010 |
Why?
|
Drug Combinations | 1 | 2006 | 2048 | 0.010 |
Why?
|
Plasmids | 1 | 2005 | 2265 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2002 | 673 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 22117 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2004 | 675 | 0.010 |
Why?
|
Blood Platelets | 1 | 2010 | 2478 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4172 | 0.010 |
Why?
|
Lymphokines | 1 | 2002 | 925 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2010 | 2218 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 3793 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12942 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2009 | 3205 | 0.010 |
Why?
|
Cladribine | 1 | 1999 | 34 | 0.010 |
Why?
|
Stromal Cells | 1 | 2004 | 1329 | 0.010 |
Why?
|
Vitamin D | 1 | 2012 | 3301 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2005 | 1834 | 0.010 |
Why?
|
Anticoagulants | 1 | 2014 | 4785 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2002 | 2261 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10549 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2010 | 3394 | 0.010 |
Why?
|
Creatinine | 1 | 2002 | 1895 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3514 | 0.010 |
Why?
|
Lymphoma | 1 | 2005 | 1899 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9476 | 0.010 |
Why?
|
Cytokines | 1 | 2010 | 7373 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2803 | 0.010 |
Why?
|
Dexamethasone | 1 | 2002 | 1946 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4569 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3268 | 0.010 |
Why?
|
HIV Infections | 1 | 2000 | 17342 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18220 | 0.010 |
Why?
|
Methotrexate | 1 | 1999 | 1716 | 0.010 |
Why?
|
Contrast Media | 1 | 2005 | 5305 | 0.010 |
Why?
|
Kidney | 1 | 2007 | 7044 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 14024 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2002 | 9586 | 0.000 |
Why?
|
Child | 1 | 2011 | 80089 | 0.000 |
Why?
|